Найден способ усилить иммунотерапию против нескольких видов рака
Найден способ усилить иммунотерапию против нескольких видов рака gazeta.press
Онкология
Иммунотерапия и CAR-T
126 материалов по теме, собраны автоматически из проверенных источников
Онкология
Targeting cell division protein CDK2 could boost immunotherapy response across a wide range of cancers
New research from Dana-Farber Cancer Institute scientists suggests that cyclin-dependent kinase 2 (CDK2) inhibitors, which are currently being tested as treatments that slow the growth of a narrow range of cancers, could potentially be more broadly applicable to a wide range of cancers when combined with immunotherapy.
Онкология
PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1
PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1 Nature
Онкология
Rethinking radiotherapy may boost immunotherapy for pancreatic cancer
Pancreatic cancer remains one of the most aggressive malignancies, with a particularly poor prognosis even when diagnosed at a localized stage. In a paper published in Nature Reviews Gastroenterology & Hepatology, researchers from GIGA and Liège University Hospital, together with colleagues from Gustave Roussy (Paris…
Онкология
CAR-T Therapy Shows Promise Against Aggressive Brain Cancer - RegMedNet
CAR-T Therapy Shows Promise Against Aggressive Brain Cancer RegMedNet
Онкология
Targeting CDK2 Could Boost Immunotherapy Response in Patients with a Wide Range of Cancers, According to Dana-Farber Science | Newswise - Newswise
Targeting CDK2 Could Boost Immunotherapy Response in Patients with a Wide Range of Cancers, According to Dana-Farber Science | Newswise Newswise
Онкология
Study uncovers why some immunotherapy-treated tumors may grow faster
A new Northwestern Medicine study has uncovered a biological mechanism that may explain why a subset of tumors unexpectedly grows at an accelerated rate after being treated with certain immunotherapies, according to findings published in the journal Cancer Discovery.
Онкология
Giving immunotherapy before surgery boosts brain tumor treatment success - News-Medical
Giving immunotherapy before surgery boosts brain tumor treatment success News-Medical
Онкология
Investigating Tumor Growth After Immunotherapy - Northwestern University
Investigating Tumor Growth After Immunotherapy Northwestern University
Онкология
Pre-surgery immunotherapy may improve treatment for deadly brain cancer
With a five-year survival rate of barely 5%, glioblastoma remains one of the deadliest brain cancers. First-line treatment consists of surgery to remove as much tumor tissue as possible.
Онкология
Dr. Antoni Ribas receives ESMO Lifetime Achievement Award for contributions to cancer immunotherapy - UCLA Health
Dr. Antoni Ribas receives ESMO Lifetime Achievement Award for contributions to cancer immunotherapy UCLA Health
Онкология
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns - BioPharma Dive
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns BioPharma Dive
Онкология
Tumor 'floor plans' may predict immunotherapy response better than current biomarkers
Spatial transcriptomics is a powerful tool for creating a detailed map of not just how genes are expressed in a piece of tissue, but also where genetic activity takes place in different cells and locations within the tissue. This is especially valuable for studying tumors, which each have their own unique…
Онкология
T cell therapy shows promise in treating aggressive brain cancer
A new phase 1 clinical trial has found that an emerging immunotherapy is promising for treating recurrent glioblastoma, a highly aggressive and fatal brain cancer. Chimeric antigen receptor T (CAR-T) cell therapy is a form of immunotherapy that modifies an individual's own T cells (a type of immune cell) so they are…
Онкология
Scientists in France pinpoint why STING pathway hasn't been harnessed for cancer therapy yet
Deep within the cellular landscape, a quiet failure was taking place, impeding a potentially successful form of cancer treatment. For years, scientists hoped an essential part of the innate immune system that detects foreign DNA in cellular cytoplasm—the STING pathway—could be harnessed for use in cancer immunotherapy.